{"id":2069,"date":"2026-10-08T20:03:57","date_gmt":"2026-10-08T20:03:57","guid":{"rendered":"https:\/\/chatscopeai.com\/news\/united-states-revokes-exempt-status-for-160-inactive-butalbital\/"},"modified":"2026-10-08T20:03:58","modified_gmt":"2026-10-08T20:03:58","slug":"united-states-revokes-exempt-status-for-160-inactive-butalbital","status":"publish","type":"post","link":"https:\/\/chatscopeai.com\/news\/united-states-revokes-exempt-status-for-160-inactive-butalbital\/","title":{"rendered":"United States Revokes Exempt Status for 160 Inactive Butalbital Products"},"content":{"rendered":"\n<p class=\"wp-block-paragraph hsn-lede\">United States drug regulators are removing 160 inactive butalbital products from the exempt prescription product list, effective 30 days after Federal Register publication scheduled for Oct. 9, 2026.<\/p>\n<p class=\"wp-block-paragraph\">The Drug Enforcement Administration (DEA), the U.S. agency that enforces federal drug laws, has issued a final determination stripping exempt status from 160 butalbital prescription products that are no longer sold, effective 30 days after its publication in the Federal Register<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\" id=\"hsn-cite-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The final determination was filed for public inspection on Oct. 8, 2026, as Federal Register document 2026-20757, with publication scheduled for Oct. 9, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\" id=\"hsn-cite-2\">2<\/a><\/sup>. It removes the inactive products from the DEA&#8217;s Table of Exempted Prescription Products, the official list of drugs spared from certain controlled-substance rules<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">In short, the DEA is cleaning up its list so it shows only butalbital products that are actually on the market. The DEA says the change will have no effect on the listed products, because they are no longer marketed, and products with active drug codes keep their exemption<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What does the DEA butalbital determination change?<\/h2>\n<p class=\"wp-block-paragraph\">The DEA is revoking the exemption for nonnarcotic prescription products whose National Drug Codes (NDCs) are inactive<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. An NDC is the unique identifier the Food and Drug Administration (FDA) assigns to each drug product. The codes are inactive because the products are no longer available, the company that applied for the exemption no longer exists, or both<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Once removed, these products will no longer count as exempt prescription products under the Controlled Substances Act, the main federal law on drugs with abuse potential<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The determination states plainly that it does not touch exempted products with active NDC numbers<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The DEA describes the action as a way to accurately portray which products are currently on the market<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The rule sits in 21 CFR Part 1308, the federal regulation that lists controlled-substance schedules, under docket DEA-1664<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Why were butalbital products exempt in the first place?<\/h2>\n<p class=\"wp-block-paragraph\">Butalbital is an intermediate-acting barbiturate, a type of sedative. The DEA classifies it as a schedule III nonnarcotic controlled substance under Controlled Substances Code Number 2100<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Schedule III drugs carry federal controls on how they are made, stored and sold.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v4\" data-at=\"why-were-butalbital-products-exempt-in-the-first-place\">\n  <div class=\"hsn-fig__table\">\n    <h4>1967 exemption criteria, per 15 mg of barbiturate<\/h4>\n    <div class=\"pcrstb-wrap\"><table>\n      <thead>\n        <tr><th>Second ingredient<\/th><th>Minimum amount<\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><th>Aspirin<\/th><td>188 mg<\/td><\/tr>\n        <tr><th>Salicylamide<\/th><td>375 mg<\/td><\/tr>\n        <tr><th>Phenacetin, acetanilid or acetaminophen<\/th><td>70 mg<\/td><\/tr>\n      <\/tbody>\n    <\/table><\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">Some butalbital products were first exempted by the FDA&#8217;s Bureau of Drug Abuse Control, a predecessor of the DEA<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. A panel of public health physicians and FDA medical officers set the exemption criteria in 1967<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The idea was that mixing butalbital with enough of another drug would cause early unpleasant side effects and so discourage abuse<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">For products combining long or intermediate barbiturates with painkillers, the 1967 criteria required a minimum amount of a second ingredient for every 15 mg of barbiturate<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>:<\/p>\n<ul>\n<li>at least 188 mg of aspirin;<\/li>\n<li>at least 375 mg of salicylamide; or<\/li>\n<li>at least 70 mg of phenacetin, acetanilid, or acetaminophen.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">The DEA later approved applications from new manufacturers using the same criteria<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. A product that met the 1967 test was treated as meeting the federal legal standard for exemption<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How many butalbital products lose exempt status?<\/h2>\n<p class=\"wp-block-paragraph\">There are 189 butalbital products listed by NDC on the DEA&#8217;s exempt table<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Using the FDA&#8217;s National Drug Code Directory and the DailyMed database of the National Library of Medicine, the DEA found that 160 of those codes are no longer active and marketed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The DEA queried both databases between Jan. 27 and Feb. 3, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v4\" data-at=\"how-many-butalbital-products-lose-exempt-status\">\n    <div class=\"hsn-fig__pie\">\n    <h4>Butalbital products on the DEA exempt table<\/h4>\n    <svg viewBox=\"0 0 100 100\" role=\"img\" aria-hidden=\"true\">\n      <path class=\"hsn-fig__slice\" data-series=\"1\" d=\"M 50.00 0.00 A 50 50 0 1 1 8.92 21.49 L 27.00 34.04 A 28 28 0 1 0 50.00 22.00 Z\"><\/path>\n      <path class=\"hsn-fig__slice\" data-series=\"2\" d=\"M 8.92 21.49 A 50 50 0 0 1 50.00 0.00 L 50.00 22.00 A 28 28 0 0 0 27.00 34.04 Z\"><\/path>\n    <\/svg>\n    <div class=\"hsn-fig__key\">\n      <span class=\"hsn-fig__keyitem\" data-series=\"1\">Inactive, removed 160<\/span>\n      <span class=\"hsn-fig__keyitem\" data-series=\"2\">Everything else 15%<\/span>\n    <\/div>\n  <\/div><\/figure>\n<p class=\"wp-block-paragraph\">That leaves 29 listed butalbital products untouched by this action. The DEA also confirmed with the FDA that the 160 products are no longer marketed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The removal list names dozens of companies, from large distributors to firms that no longer exist<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It includes products from Alvogen, Cardinal Health, Forest Pharmacal, Mallinckrodt, Mayne Pharma and Nexgen Pharma, among many others<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Mikart, Inc. appears more often than any other company, as maker or manufacturer for many brands<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The products cover several forms: tablets, capsules, oral solutions and an elixir<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Most contain 50 mg of butalbital per unit, though some contain 25 mg or 30 mg<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Familiar brand names on the list include Esgic, Phrenilin, Bupap, Allzital and Sedapap<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">What did the May 2026 proposal say?<\/h2>\n<p class=\"wp-block-paragraph\">The DEA first proposed the removal in a notice of proposed rulemaking, a draft rule opened for public comment, published on May 26, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\" id=\"hsn-cite-3\">3<\/a><\/sup>. That notice, cited as 91 FR 30527, gave the public until June 25, 2026, to comment<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v4\" data-at=\"what-did-the-may-2026-proposal-say\">\n  <div class=\"hsn-fig__axis\">\n    <h4>From proposal to final determination<\/h4>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">26 May 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Proposal published<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">25 Jun 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Comments close<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">8 Oct 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Final determination filed<\/span>\n    <\/div>\n    <div class=\"hsn-fig__ev\">\n      <span class=\"hsn-fig__evdate\">9 Oct 2026<\/span>\n      <span class=\"hsn-fig__evlab\">Scheduled publication<\/span>\n      <span class=\"hsn-fig__evsub\">Effective 30 days later<\/span>\n    <\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">The proposal invited any company that believed its product was being wrongly removed to say so, if the product was still for sale<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. Under DEA rules, an exemption can be revoked only through the same steps used to grant one: a public proposal, a comment period, and a final order setting out the findings<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How did the DEA answer the single comment?<\/h2>\n<p class=\"wp-block-paragraph\">The DEA received one comment on the proposal<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The commenter worried that the FDA directory and DailyMed may miss some codes. Products made by a contract manufacturer and sold under a private label may carry NDCs that do not appear in either database, the commenter said<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The commenter asked that all products with currently certified NDC numbers stay on the table<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The DEA replied that entries on its table are specific to each NDC, and a product must carry the exempted NDC on its label<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. It said the FDA directory covers certified finished drugs, including repackaged and relabeled ones, so it met the commenter&#8217;s request<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The DEA also contacted the FDA before the proposal and again after the comment to confirm the products were not on the market<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. None of the companies directly affected by the removals sent a comment<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The DEA published the final determination without changes<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Can these butalbital products still be sold?<\/h2>\n<p class=\"wp-block-paragraph\">Yes, under full controls. The DEA notes that a product no longer exempted may still be made and sold, as long as the company and the product meet all DEA rules and the Controlled Substances Act<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">For any firm that revives one of the 160 products, that means treating it as a <strong>schedule III controlled substance<\/strong>. Products that remain on the exempt table with active NDCs are not affected<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Summary of the DEA butalbital exemption removal<\/h2>\n<p class=\"wp-block-paragraph\">The table below sets out the main facts of the final determination.<\/p>\n<div class=\"hsn-table\">\n<div class=\"pcrstb-wrap\"><table>\n<thead><tr><th>Key Dimension<\/th><th>Details<\/th><\/tr><\/thead>\n<tbody>\n<tr><td>Regulating Authority &amp; Jurisdiction<\/td><td>Drug Enforcement Administration, U.S. Department of Justice; 21 CFR Part 1308<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Instrument<\/td><td>Final determination, docket DEA-1664, Federal Register document 2026-20757<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup><\/td><\/tr>\n<tr><td>Scope &amp; Who Must Comply<\/td><td>Makers and distributors of 160 inactive butalbital products on the exempt table<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Core Mandate \/ Key Change<\/td><td>Products lose exempt status and are removed from the Table of Exempted Prescription Products<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Products Not Affected<\/td><td>Exempted products with active NDC numbers<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Thresholds<\/td><td>160 of 189 listed butalbital products removed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Key Dates<\/td><td>Proposal May 26, 2026; comments closed June 25, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup><\/td><\/tr>\n<tr><td>Filing and Publication<\/td><td>Filed Oct. 8, 2026; publication scheduled for Oct. 9, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup><\/td><\/tr>\n<tr><td>Effective Date<\/td><td>30 days after Federal Register publication<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<tr><td>Enforcement<\/td><td>Removed products may be sold only in line with all DEA rules and the Controlled Substances Act<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup><\/td><\/tr>\n<\/tbody>\n<\/table><\/div>\n<\/div>\n<p class=\"wp-block-paragraph\">The next milestone is the formal publication in the Federal Register, scheduled for Oct. 9, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. The removal takes legal effect <strong>30 days after that publication<\/strong><sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading hsn-refs-title\">Sources<\/h2>\n<ol class=\"hsn-refs\">\n<li id=\"hsn-ref-1\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-1\" aria-label=\"Back to reference 1 in the text\">\u21a9<\/a> <a href=\"https:\/\/public-inspection.federalregister.gov\/2026-20757.pdf\" rel=\"noopener\" target=\"_blank\">2026-20757.pdf<\/a> <span class=\"hsn-refs__url\">https:\/\/public-inspection.federalregister.gov\/2026-20757.pdf<\/span><\/li>\n<li id=\"hsn-ref-2\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-2\" aria-label=\"Back to reference 2 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.federalregister.gov\/public-inspection\/2026-20757\/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products\" rel=\"noopener\" target=\"_blank\">Federal Register\n       :: \n      Public Inspection: Schedules of Controlled Substances: Removal of Exemption Status for Inactive Butalbital Products<\/a> <span class=\"hsn-refs__url\">https:\/\/www.federalregister.gov\/public-inspection\/2026-20757\/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products<\/span><\/li>\n<li id=\"hsn-ref-3\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-3\" aria-label=\"Back to reference 3 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.federalregister.gov\/documents\/2026\/05\/26\/2026-10379\/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products\" rel=\"noopener\" target=\"_blank\">Federal Register\n       :: \n      Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products<\/a> <span class=\"hsn-refs__url\">https:\/\/www.federalregister.gov\/documents\/2026\/05\/26\/2026-10379\/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>United States drug regulators are removing 160 inactive butalbital products from the exempt prescription product list, effective 30 days after Federal\u2026<\/p>\n","protected":false},"author":1,"featured_media":2067,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_regnews_id":"35683","_hsn_citations":"[{\"n\":1,\"url\":\"https:\/\/public-inspection.federalregister.gov\/2026-20757.pdf\",\"label\":\"2026-20757.pdf\"},{\"n\":2,\"url\":\"https:\/\/www.federalregister.gov\/public-inspection\/2026-20757\/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products\",\"label\":\"Federal Register\\n       :: \\n      Public Inspection: Schedules of Controlled Substances: Removal of Exemption Status for Inactive Butalbital Products\"},{\"n\":3,\"url\":\"https:\/\/www.federalregister.gov\/documents\/2026\/05\/26\/2026-10379\/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products\",\"label\":\"Federal Register\\n       :: \\n      Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products\"}]","_hsn_no_sources":"","_hsn_content_hash":"5ddd419db930151b39ea9c4385fcb169dd1751be:9266c71f30a21302d0714c511174cc32b2713a1a","_yoast_wpseo_focuskw":"butalbital products","footnotes":""},"categories":[58,18],"tags":[50],"class_list":["post-2069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-trade-regulation","tag-united-states-of-america"],"_links":{"self":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/comments?post=2069"}],"version-history":[{"count":1,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2069\/revisions"}],"predecessor-version":[{"id":2072,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/2069\/revisions\/2072"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media\/2067"}],"wp:attachment":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media?parent=2069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/categories?post=2069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/tags?post=2069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}